Open-label, Single-Center, Phase 1 Study to Estimate the Minimum Effective Dose (MED) of 131I-apamistamab for non-myeloablative conditioning in Patients with Severe Sickle Cell Disease

The purpose of this study is to research the minimum effective dose (MED) of 131 I- apamistamab conditioning for hematopoietic stem cell transplantation for patients with advanced SCD. 131 Iapamistamab is an investigational product. This means that 131 I- apamistamab has not been approved by the Food and Drug Administration (FDA) for medical use in patients. The study treatment that is given before the transplant is called the conditioning regimen. In this study, we are adding a drug called 131 I-apamistamab instead of the conditioning regimen typically given before a stem cell transplant.

Are you Eligible? (Inclusion Criteria)

• 2. Must be 12-50 years of age inclusive 3. Must have a diagnosis of sickle cell anemia (Hb SS, Sβ0 thalassemia or severe SC)